In several cancer- and non-cancer-related diseases, NR4A1 and NR4A2 are over-expressed and are targetable with receptor agonists or inverse agonists to ameliorate disease, and there are increasing studies on development of new NR4A ligands [23,30]. Here, NR4A2 is linked to cancer.